Sequel Is On a Mission To Reshape Diabetes Care

Group of young adults discussing diabetes care mission at a table.

About Sequel

Sequel, headquartered in Manchester, New Hampshire, is a company developing the next generation of transformative drug-delivery advancements. Sequel’s approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all.


Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel’s focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery.

Red brick building of Sequel headquarters with clean surroundings in Manchester, New Hampshire.

Meet the Team

We aren’t just a company, but a close-knit group of problem-solvers focused
on resolving the challenges people with diabetes face every day

Alan Lotvin - team member at Sequel.

Alan Lotvin

CEO, Co-Founder, and Director

Alan Lotvin brings 30+ years of healthcare experience from CVS Health® and Caremark® to Sequel. A trained cardiologist, he serves as a director at ProKidney.

Quraish Baldiwala - team member at Sequel.
Quraish Baldiwala
VP, Global Supply Chain

Quraish Baldiwala has held leadership roles in Supply Chain and Operations at Abbott Laboratories prior to Sequel. He serves as a board member for non-profits and as a global coach and mentor.

Steph Carroll - team member at Sequel.
Steph Carroll
Head of People & Culture

Steph Carroll serves as Head of People & Culture at Sequel Med Tech, bringing 18+ years of HR experience. She has led HR functions at healthcare companies like CVS Health and AbleTo Inc., driving organizational growth and employee engagement.

Chris Gilbert - team member at Sequel.
Chris Gilbert
VP, Marketing

Chris Gilbert serves as VP of Marketing at Sequel, bringing 25+ years of business and marketing experience. He has overseen marketing teams at diabetes-focused companies like Insulet and Seagrove Partners, driving top-line growth.

Simona Jacques, MSc - team member at Sequel.
Simona Jacques, MSc
VP, Quality

Simona Jacques brings 10+ years in Quality, Regulatory and Compliance for medical devices to Sequel. She implements Lean and Six Sigma principles and has received awards from the National Science Research Council of Canada.

Beth Keyt - team member at Sequel.
Beth Keyt
SVP, Sales, Market Access, and Government Affairs

Beth Keyt serves as SVP of Sales, Market Access, and Government Affairs, with 25+ years in medical devices and digital healthcare. She has focused on diabetes care at Dexcom and Johnson & Johnson.

Jennifer LeBlanc, MBA, BS, RN, CDCES - team member at Sequel.
Jennifer LeBlanc, MBA, BS, RN, CDCES
VP, Clinical Product Strategy

Jennifer LeBlanc brings 25+ years of clinical, research, and leadership experience in diabetes. She led innovations at Joslin Diabetes Center and received the ADCES “Innovative Use of Technology Award.”

David McAloon - team member at Sequel.
David McAloon
VP, Legal

David McAloon brings over 10 years of experience as a litigator and in-house attorney. He supported CVS Health’s diabetes care management program and has represented Fortune 50 companies in major trials, congressional investigations, and appeals before high courts.

Joanna Mitri - team member at Sequel.
Joanna Mitri
Chief Medical Officer

Joanna Mitri has dedicated her 15-year career to improving the lives of people with diabetes. An Endocrinologist, she formerly served as Associate Medical Director at Joslin Diabetes Center and Endocrinologist at PRIMA Care.

Debby Norton - team member at Sequel.
Debby Norton
VP, Customer Service

Debby Norton brings 20+ years of experience in process improvement and customer service. She started at Medtronic and worked at Insulet and CeQur, focusing on insulin delivery, bringing an empathetic perspective to customer service.

Ken Snow - team member at Sequel.
Ken Snow
Chief Scientific Officer

Ken Snow is a physician with 30+ years in clinical strategy and diabetes. As Chief Scientific Officer at Sequel, he has worked at CVS Health, Aetna, and Neurometrix, improving diabetes diagnosis and treatment.

Jay Sreedharan - team member at Sequel.
Jay Sreedharan
EVP and Chief Technology Officer

Jay Sreedharan is a senior technology leader with 25+ years of experience. He has led large engineering teams, with experience from R1 RCM and GoHealth, focused on transforming patient experience in healthcare.

Jim Wells, CPA, MBA - team member at Sequel.
Jim Wells, CPA, MBA
Controller

Jim Wells is a corporate accounting and finance professional with over 20 years of expertise. He builds high-performance teams and implements technical solutions to drive business results. Jim has worked for multinational public and large private companies before joining Sequel.

Stella Zhou - team member at Sequel.
Stella Zhou
VP, Health Solutions

Stella Zhou has 15+ years of experience bringing products to market, focusing on patient experience in diabetes care. She has commercialized healthcare products at various companies.

Board of Directors

Dean Kamen - board member of Sequel.
Dean Kamen
Co-Founder and Director

Dean Kamen, Co-Founder of Sequel, invented the first wearable insulin pump. An entrepreneur and innovator, he creates devices that improve lives and leads a team at DEKA.

Pablo Legorreta - board member of Sequel.
Pablo Legorreta
Co-Founder and Director

Pablo Legorreta, Co-Founder of Sequel and Founder/CEO of Royalty Pharma, has co-founded companies improving lives of chronic kidney disease patients.

Alan Lotvin - board member of Sequel.
Alan Lotvin
CEO, Co-Founder, and Director

Alan Lotvin brings 30+ years of healthcare experience from CVS Health® and Caremark®. A trained cardiologist, he serves as a director at ProKidney.

Maureen Toohey - board member of Sequel.
Maureen Toohey
Co-Founder and Director

Maureen Toohey has 25+ years of experience in law and medical devices. She is Managing Member of The Toohey Law Group and Deputy Executive Director of ARMI.

William Doyle - board member of Sequel.
William Doyle
Co-Founder and Director

Bill Doyle contributes 30+ years of medical device and biotech experience. He holds executive roles at Novocure, Elanco, Minerva Neurosciences, ProKidney, and previously at Johnson & Johnson.